Chronic exposure to TNFαimpairs secretion of glucagon-like peptide-1

Endocrinology (United States)

Volumn 156, Issue 11, 2015, Pages 3950-3960

  Gagnon, Jeffrey ^a,c   Sauvé, Meghan ^a   Zhao, Wen ^a   Stacey, Holly M ^a   Wiber, Stuart C ^a   Bolz, Steffen S ^a,b   Brubaker, Patricia L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c LAURENTIAN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; GLUCAGON LIKE PEPTIDE 1; MESALAZINE; MESSENGER RNA; PROGLUCAGON; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR SUBTYPE 1; UNCLASSIFIED DRUG; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; DIET INDUCED OBESITY; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERINSULINEMIA; ILEAL TISSUE; IMPAIRED GLUCOSE TOLERANCE; INCUBATION TIME; L CELL LINE; LIPID DIET; LONG TERM EXPOSURE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; ANIMAL; C57BL MOUSE; CELL LINE; DRUG EFFECTS; ENTEROENDOCRINE CELL; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENETICS; ILEUM; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECRETION (PROCESS); TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; ENTEROENDOCRINE CELLS; GENE EXPRESSION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; ILEUM; MALE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; PROGLUCAGON; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84946079534     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-1361     Document Type: Article

References (46)

1. Lobstein T, Jackson-Leach R, Moodie ML, et al. Child and adolescent obesity: part of a bigger picture. Lancet. 2015;385: 2510-2520.
2. Authors/Task Force Members, Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013; 34: 3035-3087.
3. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-A: direct role in obesity-linked insulin resistance. Science. 1993;259:87-91.
4. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415-445.
5. Herder C, Illig T, Baumert J, et al. RANTES/CCL5 gene polymorphisms, serum concentrations, and incident type 2 diabetes: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Eur JEndocrinol. 2008;158:R1-R5.
6. Zhang S, Kim KH. TNF-A inhibits glucose-induced insulin secretion in a pancreatic/3-cell line (INS-1). FEBS Lett. 1995;377: 237-239.
7. Tsiotra PC, Tsigos C, Raptis SA. TNFa and leptin inhibit basal and glucose-stimulated insulin secretion and gene transcription in the HIT-T15 pancreatic cells. Int J Obes Relat Metab Disord. 2001;25: 1018-1026.
8. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor a inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA. 1994;91:4854-4858.
9. Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman BM. Tumor necrosis factor (TNF)-A inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem. 1996;271:13018-13022.
10. Stanley TL, Zanni MV, Johnsen S, et al. TNF-A antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab. 2011;96:E146-E150.
11. Ursini F, Succurro E, Grembiale A, Rudi S, Grembiale RD, Arturi F. Sudden progression from impaired glucose tolerance to type 2 diabetes after discontinuation of administration of anti-tumor necrosis factor-A antibody infliximab. Int J Immunopathol Pharmacol. 2010;23:961-963.
12. Araújo EP, De Souza CT, Ueno M, et al. Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. Endocrinology. 2007;148:5991-5997.
13. Wascher TC, Lindeman JH, Sourij H, Kooistra T, Pacini G, Roden M. Chronic TNF-A neutralization does not improve insulin resistance or endothelial function in "healthy" men with metabolic syndrome. Mol Med. 2011;17:189-193.
14. Dominguez H, Storgaard H, Rask-Madsen C, et al. Metabolic and vascular effects of tumor necrosis factor-A blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res. 2005;42:517-525.
15. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819-837.
16. Brubaker PL. Minireview: update on incretin biology: focus on glu-cagon-like peptide-1. Endocrinology. 2010;151:1984-1989.
17. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut. 1996;38:916-919.
18. Lugari R, Dei Cas A, Ugolotti D, et al. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Horm Metab Res. 2004;36:111-115.
19. Matikainen N, Bogl LH, Hakkarainen A, et al. GLP-1 responses are heritable and blunted in acquired obesity with high liver fat and insulin resistance. Diabetes Care. 2014;37:242-251.
20. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes. 2008;57:1340-1348.
21. Pais R, Zietek T, Hauner H, Daniel H, Skurk T. RANTES (CCL5) reduces glucose-dependent secretion of glucagon-like peptides 1 and 2 and impairs glucose-induced insulin secretion in mice. Am J Physiol Gastrointest Liver Physiol. 2014;307:G330-G337.
22. Kahles F, Meyer C, Möllmann J, et al. GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes. 2014;63: 3221-3229.
23. Ellingsgaard H, Hauselmann I, Schuler B, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and a cells. Nat Med. 2011;17:1481-1489.
24. Hector J, Schwarzloh B, Goehring J, et al. TNF-A alters visfatin and adiponectin levels in human fat. Horm Metab Res. 2007;39:250-255.
25. Gagnon J, Baggio LL, Drucker DJ, Brubaker PL. Ghrelin is a novel regulator of glucagon-like peptide-1 secretion. Diabetes. 2014;64: 1513-1521.
26. Lim GE, Huang GJ, Flora N, LeRoith D, Rhodes CJ, Brubaker PL. Insulin regulates glucagon-like peptide-1 secretion from the en-teroendocrine L cell. Endocrinology. 2009;150:580-591.
27. Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes. 2009;58: 1058-1066.
28. Anini Y, Brubaker PL. Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells. Endocrinology. 2003;144:3244-3250.
29. Anini Y, Brubaker PL. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes. 2003;52:252-259.
30. Drucker DJ, Jin T, Asa SL, Young TA, Brubaker PL. Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. Mol Endocrinol. 1994;8:1646-1655.
31. Friedlander RS, Moss CE, Mace J, et al. Role of phosphodiesterase and adenylate cyclase isozymes in murine colonic glucagon-like peptide 1 secreting cells. Br J Pharmacol. 2011;163:261-271.
32. Song W, Lu X, Feng Q. Tumor necrosis factor-A induces apoptosis via inducible nitric oxide synthase in neonatal mouse cardiomyo-cytes. Cardiovasc Res. 2000;45:595-602.
33. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-A and IL-6. Diab Res Clin Pract. 2005;69:29-35.
34. Widenmaier SB, Sampaio AV, Underhill TM, McIntosh CH. Non-canonical activation of Akt/protein kinase B in/3-cells by the incretin hormone glucose-dependent insulinotropic polypeptide. J Biol Chem. 2009;284:10764-10773.
35. Nielsen ST, Lehrskov-Schmidt L, Krogh-Madsen R, et al. Tumour necrosis factor-A infusion produced insulin resistance but no change in the incretin effect in healthy volunteers. Diabetes Metab Res Rev. 2013;29:655-663.
36. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-A function. Nature. 1997;389:610-614.
37. Tsukahara T, Watanabe K, Watanabe T, et al. Tumor necrosis factor a decreases glucagon-like peptide-2 expression by up-regulating G-protein-coupled receptor 120 in Crohn disease. Am J Pathol. 2015;185:185-196.
38. Zwaveling JH, Maring JK, Clarke FL, et al. High plasma tumor necrosis factor (TNF)-A concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-A, interferon-7, and melphalan. Crit Care Med. 1996;24:765-770.
39. Rigato O, Ujvari S, Castelo A, Salomão R. Tumor necrosis factor a (TNF-A) and sepsis: evidence for a role in host defense. Infection. 1996;24:314-318.
40. Lehrskov-Schmidt L, Lehrskov-Schmidt L, Nielsen ST, Holst JJ, K ML, Solomon TP. The effects of TNF-A on GLP-1-stimulated plasma glucose kinetics. J Clin Endocrinol Metab, 2015;100: jc20144244.
41. Nakamura T, Arduini A, Baccaro B, Furuhashi M, Hotamisligil GS. Small-molecule inhibitors of PKR improve glucose homeostasis in obese diabetic mice. Diabetes. 2014;63:526-534.
42. Kim Chung le T, Hosaka T, Yoshida M, et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun. 2009;390:613-618.
43. Chen X, Baker MS, Rotramel A, Nelson JJ, Kaufman DB. TNFa impairs glucose stimulated insulin release in human islets by iCOX-independent mechanisms. J Surg Res. 2003;114:279-280.
44. De Marinis YZ, Salehi A, Ward CE, et al. GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N-And L-type Ca2+ channel-dependent exocytosis. Cell Metabol. 2010;11:543-553.
45. Hotamisligil GS. Mechanisms of TNF-A-induced insulin resistance. Exp Clin Endocrinol Diab. 1999;107:119-125.
46. McFarlane SM, Pashmi G, Connell MC, et al. Differential activation of nuclear factor-KB by tumour necrosis factor receptor subtypes. TNFR1 predominates whereas TNFR2 activates transcription poorly. FEBS Lett. 2002;515:119-126.